Udvalget for Humanmedicinske Lægemidler (CHMP) fandt, at det i overensstemmelse med EU - kravene er påvist, at Retacrits kvalitet, sikkerhed og virkning svarer til EPREX/ ERYPO’ s.
The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Retacrit has been shown to have a comparable quality, safety and efficacy profile to EPREX/ ERYPO.